Brief: Eledon To Present Data From Ongoing Phase 1B Trial Evaluating Tegoprubart In Kidney Transplantation At The World Congress Of Nephrology 2023
23/03/2023 13:12
March 23 (Reuters) - Eledon Pharmaceuticals Inc
ELDN.O :
* ELEDON TO PRESENT DATA FROM ONGOING PHASE 1B TRIAL
EVALUATING
TEGOPRUBART IN KIDNEY TRANSPLANTATION AT THE WORLD CONGRESS OF
NEPHROLOGY 2023
Source text for Eikon: ID:nGNX6vZp4b
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial